Response to pathophysiological relevance of proteomics investigations of drug-induced hepatotoxicity in HepG2 cells

Toxicological Sciences

Volumn 121, Issue 2, 2011, Pages 431-433

  Van Summeren, Anke ^a   Renes, Johan ^a   Mariman, Edwin C M ^a   Kleinjans, Jos C S ^a   van Delft, Joost H M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYCLOSPORIN A; CYTOCHROME P450 2E1; PARACETAMOL;

CYTOTOXICITY; DRUG METABOLISM; HUMAN; LETTER; LIVER CELL; LIVER TOXICITY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEOMICS; TOXICITY TESTING;

EID: 79957833068     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr055     Document Type: Letter

References (33)

1. Amacher, D. E. (2010). The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol. 245, 134-142.
2. Bessems, J. G., and Vermeulen, N. P. (2001). Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31, 55-138.
3. Blomme, E. A., Yang, Y., and Waring, J. F. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 186, 22-31.
4. Boess, F., Kamber, M., Romer, S., Gasser, R., Muller, D., Albertini, S., and Suter, L. (2003). Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73, 386-402.
5. Borenfreund, E., Babich, H., and Martin-Alguacil, N. (1988). Comparisons of two in vitro cytotoxicity assays-the neutral red (NR) and tetrazolium MTT tests. Toxicol. In Vitro 2, 1-6.
6. Burczynski, M. E., McMillian, M., Ciervo, J., Li, L., Parker, J. B., Dunn, R. T., II., Hicken, S., Farr, S., and Johnson, M. D. (2000). Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58, 399-415.
7. Choi, S., Park, S. Y., Jeong, J., Cho, E., Phark, S., Lee, M., Kwak, D., Lim, J. Y., Jung, W. W., and Sul, D. (2010). Identification of toxicological biomarkers of di(2-ethylhexyl) phthalate in proteins secreted by HepG2 cells using proteomic analysis. Proteomics 10, 1831-1846.
8. Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., et al. (2009). Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol. Appl. Pharmacol. 237, 317-330.
9. Fannin, R. D., Russo, M., O'Connell, T. M., Gerrish, K., Winnike, J. H., Macdonald, J., Newton, J., Malik, S., Sieber, S. O., Parker, J., et al. (2010). Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 51, 227-236.
10. Hamid, R., Rotshteyn, Y., Rabadi, L., Parikh, R., and Bullock, P. (2004). Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. In Vitro 18, 703-710.
11. Hart, S. N., Li, Y., Nakamoto, K., Subileau, E. A., Steen, D., and Zhong, X. B. (2010). A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38, 988-994.
12. Hewitt, N. J., and Hewitt, P. (2004). Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34, 243-256.
13. Hockley, S. L., Mathijs, K., Staal, Y. C., Brewer, D., Giddings, I., van Delft, J. H., and Phillips, D. H. (2009). Interlaboratory and interplatform comparison of microarray gene expression analysis of HepG2 cells exposed to benzo(a)pyrene. Omics 13, 115-125.
14. Hong, Y., Muller, U. R., and Lai, F. (2003). Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol. In Vitro 17, 85-92.
15. Huang, J., Shi, W., Zhang, J., Chou, J. W., Paules, R. S., Gerrish, K., Li, J., Luo, J., Wolfinger, R. D., Bao, W., et al. (2010). Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J. 10, 267-277.
16. Jaeschke, H., McGill, M. R., and Ramachandran, A. Pathophysiological relevance of proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol. Sci. Advance Access published on March 7, 2011; doi:10.1093/toxsci/kfr053.
17. Jennen, D. G., Magkoufopoulou, C., Ketelslegers, H. B., van Herwijnen, M. H., Kleinjans, J. C., and van Delft, J. H. (2010). Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol. Sci. 115, 66-79.
18. Kienhuis, A. S., van de Poll, M. C., Dejong, C. H., Gottschalk, R., van Herwijnen, M., Boorsma, A., Kleinjans, J. C., Stierum, R. H., and van Delft, J. H. (2009a). A toxicogenomics-based parallelogram approach to evaluate the relevance of coumarin-induced responses in primary human hepatocytes in vitro for humans in vivo. Toxicol. In Vitro 23, 1163-1169.
19. Kienhuis, A. S., van de Poll, M. C., Wortelboer, H., van Herwijnen, M., Gottschalk, R., Dejong, C. H., Boorsma, A., Paules, R. S., Kleinjans, J. C., Stierum, R. H., et al. (2009b). Parallelogram approach using rat-human in vitro and rat in vivo toxicogenomics predicts acetaminophen-induced hepatotoxicity in humans. Toxicol. Sci. 107, 544-552.
20. Knasmuller, S., Mersch-Sundermann, V., Kevekordes, S., Darroudi, F., Huber, W. W., Hoelzl, C., Bichler, J., and Majer, B. J. (2004). Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198, 315-328.
21. Knowles, B. B., Howe, C. C., and Aden, D. P. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209, 497-499.
22. Mathijs, K., Kienhuis, A. S., Brauers, K. J., Jennen, D. G., Lahoz, A., Kleinjans, J. C., and van Delft, J. H. (2009). Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab. Dispos. 37, 1305-1311.
23. McGill, M. R., Yan, H., Ramachandran, A., Murray, G. J., Rollins, D. E., and Jaeschke, H. (2011). HepaRG cells: a human model to study mechanisms of acetaminophen toxicity. Hepatology 53, 974-982.
24. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65, 55-63.
25. O'Brien, P., and Haskins, J. R. (2007). In vitro cytotoxicity assessment. Methods Mol. Biol. 356, 415-425.
26. Schoonen, W. G., Westerink, W. M., and Horbach, G. J. (2009). Highthroughput screening for analysis of in vitro toxicity. EXS 99, 401-452.
27. Slany, A., Haudek, V. J., Zwickl, H., Gundacker, N. C., Grusch, M., Weiss, T. S., Seir, K., Rodgarkia-Dara, C., Hellerbrand, C., and Gerner, C. (2010). Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J. Proteome Res. 9, 6-21.
28. Staal, Y. C., van Herwijnen, M. H., van Schooten, F. J., and van Delft, J. H. (2006). Modulation of gene expression and DNA adduct formation in HepG2 cells by polycyclic aromatic hydrocarbons with different carcinogenic potencies. Carcinogenesis 27, 646-655.
29. van Delft, J. H., van Agen, E., van Breda, S. G., Herwijnen, M. H., Staal, Y. C., and Kleinjans, J. C. (2004). Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25, 1265-1276.
30. Van Summeren, A., Renes, J., Bouwman, F. G., Noben, J. P., van Delft, J. H., Kleinjans, J. C., and Mariman, E. C. (2011). Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol. Sci. 120, 109-122.
31. Westerink, W. M., and Schoonen, W. G. (2007). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1581-1591.
32. Westerink, W. M., Stevenson, J. C., Horbach, G. J., and Schoonen, W. G. (2010). The development of RAD51C, Cystatin A, p53 and Nrf2 luciferasereporter assays in metabolically competent HepG2 cells for the assessment of mechanism-based genotoxicity and of oxidative stress in the early research phase of drug development. Mutat. Res. 696, 21-40.
33. Wilkening, S., and Bader, A. (2003). Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J. Biochem. Mol. Toxicol. 17, 207-213.